Financial News

Bristol-Myers Squibb Company (NYSE: BMY) will present at the 31^st Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2013, in San Francisco.

Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced today that the European Commission has approved ELIQUIS^® (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. ELIQUIS is the only oral anticoagulant that has demonstrated superior risk reduction versus warfarin in the three important outcomes of stroke and systemic embolism, major more...

Bristol-Myers Squibb Company (NYSE: BMY) today announced new Phase II data demonstrating that the dual regimen of the investigational NS5A replication complex inhibitor daclatasvir (DCV) and the investigational NS3 protease inhibitor asunaprevir (ASV), without interferon or ribavirin, achieved high rates of sustained virologic respo more...

Bristol-Myers Squibb Company (NYSE: BMY) will present at the 2012 Credit Suisse Healthcare Conference on Wednesday, November 14, 2012, in Phoenix. Douglas Manion, senior vice president, Development, Neuroscience, Virology and Japan, will make a formal presentation about the company at 1:30 p.m. MT (3:30 p.m. ET). more...

Bristol-Myers Squibb Company (NYSE:BMY) announced today that 27 abstracts on the Company’s research in liver disease have been accepted for presentation at The Liver Meeting^® 2012, the 63^rd annual meeting of The American Association for the Study of Liver Diseases (AASLD), in Boston, November 9 – 13. more...

Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the third quarter on Wednesday, October 24, 2012. During a conference call at 10:00 a.m. ET on October 24, company executives will review financial information and will address inquiries from investors and analysts. more...